Gavi, the Vaccine Alliance

What Gavi, the Vaccine Alliance does

Gavi, the Vaccine Alliance is a Swiss foundation with international institution status, founded in 2000 as a public-private partnership to expand equitable access to immunization in lower-income countries. It operates as a market-shaping financing platform that aggregates vaccine demand across 78 eligible lower-income countries, negotiates volume-based pricing with manufacturers, and channels capital and technical assistance through implementing governments and multilateral partners including UNICEF (procurement), WHO (technical guidance), and the World Bank (financing). Its core technology is the market-shaping mechanism itself: innovative finance instruments including the International Finance Facility for Immunisation (IFFIm), the Pneumococcal Advance Market Commitment (AMC), the Gavi Matching Fund, and the Day Zero Financing Facility, which collectively mobilize sovereign donor capital, philanthropic grants, country co-financing ($302M in 2025), and capital-market borrowings to fund vaccine procurement at scale.

Gavi's product portfolio spans 20 infectious diseases and includes the Gavi 6.0 Strategic Framework (2026-2030), the Gavi Leap reform programme, the African Vaccine Manufacturing Accelerator (AVMA+, $189M), the First Response Fund for outbreak emergencies, and the VaccinesWork digital media platform. Its business model is a five-year replenishment cycle funded primarily by sovereign governments (over $9 billion secured for 2026-2030 from 55 countries and donors at the June 2025 Brussels summit, including $1.6B from the Gates Foundation), supplemented by country co-financing, innovative finance proceeds, and private sector partnerships. Distribution is handled through UNICEF as the primary procurement agent and through national immunization programmes in implementing countries. Since inception, Gavi has helped immunize over 1.2 billion children, avert 20.6 million future deaths, and generate $280+ billion in economic benefits across supported countries.

Name

Gavi, the Vaccine Alliance

Legal name

The Gavi Alliance

Website

https://gavi.org

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

Gavi, the Vaccine Alliance is a Geneva-based public-private partnership founded in 2000 that finances and coordinates immunization programmes across 78 lower-income countries, leveraging innovative finance, UNICEF procurement, and donor capital to vaccinate over half the world's children against 20 infectious diseases.

Ownership category

akta.pro rank

Product category

Global Immunization Financing

NAICS

Voluntary Health Organizations (813212), Grantmaking and Giving Services (81321)

SIC

Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Immunization & Vaccine Access Partnerships (Global Vaccine Alliances) (HLAJAOAF)

akta.pro secondary industries

Immunization & Vaccine Delivery Programs (BPADAIAB), Infectious Disease & Immunization Program Funding (HLAJALAH), Funding, Reimbursement & Vaccines-for-Children (VFC)/Public Purchase Programs (HLAJAHAK)

Keywords

• Vaccine financing
• Immunization programs
• Vaccine market shaping
• Global health partnerships
• Public health funding

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Supply Chain, Marketing or Sales, Others

Revenue model

1. Government Donor Funding: Gavi is funded by sovereign governments through five-year replenishment cycles. Donor governments contribute based on GDP and other factors. At the June 2025 Brussels summit, over $9 billion was secured from 55 countries and donors for the 2026-2030 strategic period.
2. Foundation and Private Sector Contributions: Major foundations including the Gates Foundation provide substantial grants. The Gates Foundation contributed $1.6 billion at the 2025 replenishment. Corporate partners contribute through the Gavi Matching Fund and other innovative financing mechanisms.
3. Country Co-Financing: Implementing countries contribute to the cost of vaccines through co-financing arrangements. Lower-income countries collectively invested a record US$302 million in 2025, with countries contributing $1.1 billion over the past five years.
4. Innovative Finance Mechanisms: Gavi leverages IFFIm to raise finance in international capital markets to support programmes. The Pneumococcal Advance Market Commitment (AMC) incentivizes vaccine development through guaranteed purchase commitments.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Gavi funds and coordinates the procurement, introduction, and delivery of vaccines against 20 infectious diseases (including Ebola, malaria, mpox, HPV, and routine childhood immunizations) for 78 lower-income countries. It does not sell products directly; instead it pools donor commitments, negotiates affordable pricing with manufacturers, channels vaccines through UNICEF, and provides co-financing and technical assistance to country governments running national immunization programmes.

Product overview

Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate more than half the world's children against some of the world's deadliest diseases. Rather than a unified software product, Gavi operates as a coordination and funding mechanism offering multiple programs including the Gavi 6.0 Strategic Framework (2026-2030), the Gavi Leap reform program, the African Vaccine Manufacturing Accelerator (AVMA+), the First Response Fund for outbreak emergencies, the COVAX Rapid Financing Facility, the Digital Health Information Strategy, and the VaccinesWork digital media platform. Gavi supports vaccines against 20 infectious diseases including Ebola, malaria, mpox, HPV, and rabies, spanning vaccine support, health systems strengthening, and market shaping activities.

Differentiator

Problem solved

Functional benefit

Brands

• VaccinesWork: Award-winning digital platform hosted by Gavi covering news, features and explainers from every corner of global health and immunisation.
• Gavi Leap
• COVAX
• AVMA+ (African Vaccine Manufacturing Accelerator)

Products and services

• Gavi 6.0 Strategic Framework (2026–2030) Five-year strategic framework providing access to Gavi's portfolio of life-saving vaccines for implementing country governments and partners during the 2026–2030 period.
• African Vaccine Manufacturing Accelerator (AVMA+) Accelerator programme providing guaranteed procurement, technology transfer support, and capacity building to African vaccine manufacturers, addressing regulatory and market-entry bottlenecks.
• First Response Fund Surge-financing mechanism enabling rapid deployment of vaccines during outbreaks and epidemics, with agile coalition financing for Day Zero intervention.
• COVAX Rapid Financing Facility Financing facility providing up to US$1 billion to accelerate purchase and delivery of COVID-19 vaccines and supplies for developing countries, in partnership with the US DFC.
• R21/Matrix-M Malaria Vaccine Programme Affordable malaria vaccine procurement programme offering R21/Matrix-M at $2.99 per dose to supported countries, with multi-year pricing agreement covering 25 African countries.
• VaccinesWork Digital Platform

Quantifiable outcome

• 1.2 billion children vaccinated, 20.6 million deaths averted, $280+ billion in economic benefits since 2000
• +4 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered flagship and core.

• UNICEF (Bundibugyo Ebola Initiative)flagshipStrategic or Co-development Partner · 25 June 2026UNICEF and Gavi jointly launched a Request for Expression of Interest for Bundibugyo Ebola vaccine development. UNICEF issued the EOI inviting developers to submit vaccine candidate details, with Gavi committing $50 million through its First Response Fund to support manufacturing and rapid deployment.
• PfizercoreTechnology or Integration · 22 October 2024Pfizer supplies pneumococcal conjugate vaccines on a not-for-profit basis to 57 Gavi-eligible countries. Pfizer reached the milestone of 1 billion doses supplied through Gavi, with the milestone dose delivered to Ethiopia's national immunization programme. The collaboration has protected over 300 million children from pneumococcal disease.
• UNICEFcoreStrategic or Co-development PartnerUNICEF is the world's largest buyer and supplier of vaccines for developing countries and serves as a pivotal partner in the Vaccine Alliance. UNICEF handles procurement and supply chain logistics for Gavi-supported vaccines, reaching children in the most remote and underserved communities through national immunization programmes.
• World Health Organization (WHO)coreStrategic or Co-development PartnerAs the UN's specialist agency on global health issues, WHO provides technical expertise and normative guidance to the Vaccine Alliance. WHO sets immunization policies, provides country-level technical assistance, and coordinates outbreak response through global health emergency mechanisms.
• World BankcoreStrategic or Co-development PartnerThe World Bank brings expertise in development financing to the Vaccine Alliance, providing loans, grants, and technical assistance for health system strengthening in implementing countries. The Bank supports countries to finance immunization programmes and transition to sustainable domestic financing.
• CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development PartnerCEPI coordinates with Gavi on outbreak vaccine development, including the urgent plan for Bundibugyo Ebola vaccine response. CEPI and Gavi issued joint calls for accelerating vaccine access during the 2026 Ebola outbreak caused by the Bundibugyo virus.

Scale indicators23 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• UNICEF Supply Division: UNICEF is Gavi's primary procurement partner and the world's largest vaccine buyer for developing countries, executing bulk procurement and supply chain logistics on Gavi's behalf. The two organizations are operationally intertwined, with UNICEF handling the physical vaccine distribution while Gavi provides financing.
• Gavi (Global Alliance for Vaccines and Immunization): Listed as the anchor; included for completeness as the primary reference entity.
• The Global Fund to Fight AIDS, Tuberculosis and Malaria: Parallel global health financing partnership using similar multi-donor replenishment model to fund disease control programs in lower-income countries. Directly comparable in structure, governance (public-private board), and 5-year replenishment cycle approach to mobilizing billions for health programs.
• Coalition for Epidemic Preparedness Innovations (CEPI): Direct partner and peer in the global vaccine ecosystem, co-leading COVAX with Gavi. CEPI focuses on vaccine R&D for epidemic threats while Gavi handles procurement and delivery — making them complementary but comparable in mission and donor base.
• PATH: Global health non-profit with deep vaccine programs including the Malaria Vaccine Initiative and significant involvement in introducing new vaccines in lower-income countries. Comparable to Gavi as a coordinating and financing entity for vaccine access programs.
• Clinton Health Access Initiative (CHAI): Works in lower-income countries on market-shaping for vaccines, medicines, and diagnostics, with overlapping country relationships to Gavi's. CHAI negotiates pricing and supports health system strengthening in similar geographies, making it a comparable operator in vaccine access.

Broad incumbents

• World Health Organization (WHO): Gavi's core institutional partner and a broader incumbent in global health governance. WHO sets immunization policy and provides technical guidance that Gavi finances, creating overlapping mandate in global health architecture.
• Bill & Melinda Gates Foundation: Gavi's largest single donor ($1.6B at 2025 replenishment, $750M founding seed) and a broader incumbent in global health financing. The Foundation operates across a far wider portfolio but is the closest comparable funder of immunization and global health systems.
• Wellcome Trust: Major UK-based foundation funding global health research and epidemic preparedness. Contributes to CEPI and various vaccine initiatives, making it a comparable funder with overlapping donor relationships to Gavi.

Emerging players

• Medicines for Malaria Venture (MMV): Product development partnership focused on malaria treatments and now adjacent in malaria vaccines, with a similar donor-funded, multi-stakeholder structure. Operates at smaller scale than Gavi but is comparable in public-private partnership model and malaria focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/gavi
• YouTubeyoutube.com/@Gavi
• Facebookfacebook.com/GAVI
• LinkedInlinkedin.com/company/gavi
• Instagraminstagram.com/gavialliance
• TikToktiktok.com/@gavialliance

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gavi, the Vaccine Alliance